Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: Interim analysis

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In the TAX 326 trial, 1,220 chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer have been randomized to receive one of three regimens: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 every 3 weeks; docetaxel 75 mg/m2 plus carboplatin to an area under the curve of 6 mg/mL · min every 3 weeks; or a control arm of vinorelbine 25 mg/m2 weekly plus cisplatin 100 mg/m2 monthly. The treatment and toxicity data presented are based on a planned preliminary analysis conducted after 601 patients had been enrolled. The median age of patients randomized was 60 years and 73% were male. The majority of patients had a Karnofsky score of 80 or greater, two thirds had stage IV disease and 35% had three or more sites of organ involvement. While the relative dose intensity for docetaxel was 0.97 both when combined with cisplatin and when combined with carboplatin, the corresponding figure for vinorelbine was 0.68, reflecting the frequent need for dose reduction when combined with cisplatin on the schedule used. Hematologic toxicities were tolerable and comparable across the three arms of the trial, and the rate of febrile neutropenia was below 5% in all cases. The incidence of nonhematologic toxicities also was similar, although nausea and vomiting appeared to be less frequent among patients assigned to docetaxel plus carboplatin than among patients receiving comparator regimens.

Original languageEnglish (US)
Pages (from-to)10-14
Number of pages5
JournalSeminars in oncology
Volume28
Issue number3 SUPPL. 9
StatePublished - Jan 1 2001

Fingerprint

docetaxel
Carboplatin
Non-Small Cell Lung Carcinoma
Cisplatin
Febrile Neutropenia
Nausea
Area Under Curve
Vomiting
vinorelbine
Appointments and Schedules

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

@article{ead26381552d435fb7b5dd88aaa7404b,
title = "Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: Interim analysis",
abstract = "In the TAX 326 trial, 1,220 chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer have been randomized to receive one of three regimens: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 every 3 weeks; docetaxel 75 mg/m2 plus carboplatin to an area under the curve of 6 mg/mL · min every 3 weeks; or a control arm of vinorelbine 25 mg/m2 weekly plus cisplatin 100 mg/m2 monthly. The treatment and toxicity data presented are based on a planned preliminary analysis conducted after 601 patients had been enrolled. The median age of patients randomized was 60 years and 73{\%} were male. The majority of patients had a Karnofsky score of 80 or greater, two thirds had stage IV disease and 35{\%} had three or more sites of organ involvement. While the relative dose intensity for docetaxel was 0.97 both when combined with cisplatin and when combined with carboplatin, the corresponding figure for vinorelbine was 0.68, reflecting the frequent need for dose reduction when combined with cisplatin on the schedule used. Hematologic toxicities were tolerable and comparable across the three arms of the trial, and the rate of febrile neutropenia was below 5{\%} in all cases. The incidence of nonhematologic toxicities also was similar, although nausea and vomiting appeared to be less frequent among patients assigned to docetaxel plus carboplatin than among patients receiving comparator regimens.",
author = "Chandra Belani",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "28",
pages = "10--14",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 9",

}

TY - JOUR

T1 - Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer

T2 - Interim analysis

AU - Belani, Chandra

PY - 2001/1/1

Y1 - 2001/1/1

N2 - In the TAX 326 trial, 1,220 chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer have been randomized to receive one of three regimens: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 every 3 weeks; docetaxel 75 mg/m2 plus carboplatin to an area under the curve of 6 mg/mL · min every 3 weeks; or a control arm of vinorelbine 25 mg/m2 weekly plus cisplatin 100 mg/m2 monthly. The treatment and toxicity data presented are based on a planned preliminary analysis conducted after 601 patients had been enrolled. The median age of patients randomized was 60 years and 73% were male. The majority of patients had a Karnofsky score of 80 or greater, two thirds had stage IV disease and 35% had three or more sites of organ involvement. While the relative dose intensity for docetaxel was 0.97 both when combined with cisplatin and when combined with carboplatin, the corresponding figure for vinorelbine was 0.68, reflecting the frequent need for dose reduction when combined with cisplatin on the schedule used. Hematologic toxicities were tolerable and comparable across the three arms of the trial, and the rate of febrile neutropenia was below 5% in all cases. The incidence of nonhematologic toxicities also was similar, although nausea and vomiting appeared to be less frequent among patients assigned to docetaxel plus carboplatin than among patients receiving comparator regimens.

AB - In the TAX 326 trial, 1,220 chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer have been randomized to receive one of three regimens: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2 every 3 weeks; docetaxel 75 mg/m2 plus carboplatin to an area under the curve of 6 mg/mL · min every 3 weeks; or a control arm of vinorelbine 25 mg/m2 weekly plus cisplatin 100 mg/m2 monthly. The treatment and toxicity data presented are based on a planned preliminary analysis conducted after 601 patients had been enrolled. The median age of patients randomized was 60 years and 73% were male. The majority of patients had a Karnofsky score of 80 or greater, two thirds had stage IV disease and 35% had three or more sites of organ involvement. While the relative dose intensity for docetaxel was 0.97 both when combined with cisplatin and when combined with carboplatin, the corresponding figure for vinorelbine was 0.68, reflecting the frequent need for dose reduction when combined with cisplatin on the schedule used. Hematologic toxicities were tolerable and comparable across the three arms of the trial, and the rate of febrile neutropenia was below 5% in all cases. The incidence of nonhematologic toxicities also was similar, although nausea and vomiting appeared to be less frequent among patients assigned to docetaxel plus carboplatin than among patients receiving comparator regimens.

UR - http://www.scopus.com/inward/record.url?scp=0034978657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034978657&partnerID=8YFLogxK

M3 - Article

C2 - 11441409

AN - SCOPUS:0034978657

VL - 28

SP - 10

EP - 14

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 9

ER -